entertainment -WSS

entertainment

author：comprehensive 2025-10-02 22:26:24 - browse：14

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Eli Lilly, Pfizer, and others want in on the online prescription market

focus

WSS

Unmasking the 'centricity' illusion in clinical trials

Protect nursing home residents from future pandemics

eGenesis tests gene

Lawsuit challenges CMS nursing home minimum staffing rule

Clinicians often fail to acknowledge the pain caused by long Covid

Readout Newsletter: Merck, J&J, and long Covid

entertainment

entertainment

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Parkinson’s finding may lead to tests and, someday, treatments

After affirmative action ruling, medical educators look to 'holistic review'

The surgeon had a dilemma only a Nazi medical text could resolve

New air purifier tech could be key to improving indoor air quality

Clinicians often fail to acknowledge the pain caused by long Covid

Medicare details structure of new drug price negotiation program

NIH director takes cautious approach to Biden drug pricing priority

Activists slam private health insurers over coverage restrictions

Decentralized clinical trials need collaboration to achieve wider use

focus

Prior authorization will have to move faster under new Biden rule

The Bio Revolution is changing business and society

Prior authorization will have to move faster under new Biden rule

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Francis Collins on trust in science and how Covid communications failed

Stroke rates rising, especially in working

focus

focus

focus

focus